Atlas Trials

Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test

Clinical trial NCT03864978 · UNKNOWN

Trial details

NCT number
NCT03864978
Sponsor
Alfasigma S.p.A.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Papulopustular Rosacea
Start date
2018-06-22
Primary completion
2020-04-01
Enrollment
236

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.